Last reviewed · How we verify
Sinemet 25-100 Oral Tablet
At a glance
| Generic name | Sinemet 25-100 Oral Tablet |
|---|---|
| Also known as | Carbidopa / Levodopa |
| Sponsor | XenoPort, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Ranging Study of Carbidopa-levodopa (PHASE2)
- Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD) (PHASE2)
- Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure (PHASE2)
- L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults (PHASE4)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions (PHASE1)
- An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects (PHASE1, PHASE2)
- Improving Quality of Life in Early Parkinson's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinemet 25-100 Oral Tablet CI brief — competitive landscape report
- Sinemet 25-100 Oral Tablet updates RSS · CI watch RSS
- XenoPort, Inc. portfolio CI